This paper presents the results of a contingent valuation study
measuring willingness to pay (WTP) for treatment of patients with von
Willebrand's disease. Median WTP for treatment of this disorder was
$1,500 or $3,500, depending on
how the initial bid was structured.
Regression analysis shows that income, education, and a category rating
scale for health status were significant in predicting WTP. The adjusted
annual WTP was $2,178. WTP surveys may increasingly be
useful for health technology assessment. Starting point bias in how the bids are structured must be
recognized.